Contents

Lenabasum

Chemical compound

Lenabasum

Clinical data
Trade names	Lenabasum
Routes of administration	Oral
ATC code	None
Legal status
Legal status	Investigational
Pharmacokinetic data
Metabolism	Minimal
Identifiers
IUPAC name (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid
CAS Number	137945-48-3 N
PubChem CID	3083542
ChemSpider	21106251 Y
UNII	OGN7X90BT8
ChEMBL	ChEMBL456341 N
CompTox Dashboard (EPA)	DTXSID40900959
Chemical and physical data
Formula	C25H36O4
Molar mass	400.559 g·mol−1
3D model (JSmol)	Interactive image
SMILES OC(C1=CC[C@](C(C)(C)OC2=C3C(O)=CC(C(C)(C)CCCCCC)=C2)([H])[C@@]3([H])C1)=O
InChI InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10-11,14-16,18-19,26H,6-9,12-13H2,1-5H3,(H,27,28)/t16?,18-,19-/m1/s1 Y Key:QHGPTMABBHVVQU-VOBHOPKGSA-N Y
NY (what is this?)  (verify)

Lenabasum (also known as ajulemic acid, 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab) is a synthetic cannabinoid that shows anti-fibrotic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high".^[1] Although its design was inspired by a metaboliteofdelta-9-THC known as delta-9-THC-11-oic acid, lenabasum is an analog of the delta-8-THC metabolite delta-8-THC-11-oic acid.^[2][3] It is being developed for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis.^[4] It does not share the anti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve.^[5] Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of the CB₂ receptor leading to production of specialized proresolving eicosanoids such as lipoxin A4 and prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced by tetrahydrocannabinol.^[6] Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases.^[7] Development since been discontinued.^[8]